An analysis on global drug development status of rheumatoid arthritis
文献类型：期刊论文
| 作者 | Liu Lili; Mao Yanyan; Gao Liubin
|
| 刊名 | Science & Technology Review
 |
| 出版日期 | 2016 |
| 卷号 | 34期号:24页码:44-56 |
| 关键词 | rheumatoid arthritis autoimmune disease biological agents small molecule drugs tumor necrosis factor |
| ISSN号 | 1000-7857 |
| 其他题名 | 类风湿关节炎全球药物研发状况分析 |
| 文献子类 | Review |
| 英文摘要 | Rheumatoid arthritis (RA) is an autoimmune disease, which is a worldwide disease, with a global prevalence rate of about 0.24%. RA pathogenesis is complex and has a high disability rate, depressing the life quality of patients seriously and aggravating the economic burden of the society. Effective treatment of RA has become a focus of the global pharmaceutical industry. According to the IMS Health statistics, the global drug expenditure for the treatment of RA amounted to $21.4 billion in 2015. This paper uses literature investigation, database search, such as Thomson Reuters, IMS Health etc., as well as data statistics and analysis, to make an analysis on the global RA drug development status, market, targets, patent and other information. Medicine treatment for RA includes anti- inflammatory drugs, anti-rheumatic drugs, hormone drugs, biological agents, combination of drugs, immune reconstitution, etc. Therapeutic target involves tumor necrosis factor alpha, cycloxygenase, B-lymphocyte antigen, interleukin, nuclear transcription factor kB, small molecule kinase and so on. In recent years, the development of biotechnology drugs in the treatment of RA and other autoimmune diseases has made an unprecedented success, small molecule drugs and biosimilar products will also play an important role in the future market. |
| WOS研究方向 | Pharmacology & Pharmacy (provided by Clarivate Analytics) |
| 语种 | 中文 |
| CSCD记录号 | CSCD:5884690 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/269222]  |
| 专题 | 信息中心 |
| 通讯作者 | Liu Lili |
| 作者单位 | Intelligence Research Department, Information Center, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 201203, China. |
| 推荐引用方式 GB/T 7714 | Liu Lili,Mao Yanyan,Gao Liubin. An analysis on global drug development status of rheumatoid arthritis[J]. Science & Technology Review,2016,34(24):44-56. |
| APA | Liu Lili,Mao Yanyan,&Gao Liubin.(2016).An analysis on global drug development status of rheumatoid arthritis.Science & Technology Review,34(24),44-56. |
| MLA | Liu Lili,et al."An analysis on global drug development status of rheumatoid arthritis".Science & Technology Review 34.24(2016):44-56. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。